secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001846253-25-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb reports Q2 2025 revenue $3.9M, net loss $15.9M; affirms $20-25M FY revenue guidance
--------------------------------------------------------------------------------

- Q2 revenue $3.9M (down 49% YoY) on lower milestone and service revenue; net loss $15.9M ($0.15/sh) vs $13.6M ($0.13) in Q2 2024.
- 2025 guidance: revenue $20M-$25M, operating costs $85M-$90M, cash use expected below 2024's $38.9M (ex-ATM).
- 100 active partners and 381 active programs as of June 30, 2025, including 32 OmniAb-derived programs in clinical development.
- Sold small-molecule Kv7.2 program to Angelini Pharma for $3M upfront; eligible for >$170M milestones plus royalties.
- Launched xPloration Partner Access Program for high-throughput B-cell screening; xPloration won 2025 Best of Show at PEGS Boston.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625325000064/0001846253-25-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625325000064/oabi-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001846253-25-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer